Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Regeneron signs Mammoth gene editing deal worth $100M upfront
Regeneron is signing another major deal in gene editing—and, this time, it’s Mammoth.
Annalee Armstrong
Apr 25, 2024 8:49am
Boehringer signs $1.3B MASH collab with RNA biotech Ochre
Apr 22, 2024 8:45am
Sanofi shrinks $6B biobucks deal with IGM
Apr 17, 2024 11:05am
Lilly's Prevail walks away from Precision gene editing collab
Apr 17, 2024 8:48am
Connect uncouples from Pfizer by scrapping eczema pact
Apr 17, 2024 6:38am
Takeda inks sweet $1.2B-plus immuno-oncology deal with Kumquat
Apr 16, 2024 11:34am